64 results about "Pathophysiology" patented technology

The invention discloses a disease risk assessment method and screening device based on a multi-group student physical collaborative digital network, and relates to the field of intelligent medical detection. In order to solve the defect that multi-omics-level system collaborative analysis and robust risk assessment are difficult to realize in the prior art, the technical scheme provided by the invention is as follows: acquiring a plasma sample, acquiring a spectral signal by adopting an attenuated total reflection Fourier transform infrared spectrum, and establishing a plasma spectrum digital information space; the method comprises the following steps: constructing a biological collaborative digital network containing four nodes of protein, lipid, saccharides and nucleic acid based on pathophysiology priori knowledge, and defining node strength, edge weight and network collaborative efficiency; a health baseline configuration file is established by using a health sample, a standardized deviation score of a to-be-tested sample is calculated, a comprehensive risk score is obtained, a disease screening result is output in combination with a machine learning model, and digital evaluation of multi-omics collaborative characteristics is realized. The method is suitable for non-invasive rapid screening and risk assessment work of neurodegenerative diseases and mental diseases.

The invention discloses an injury condition simulation system based on treatment feedback and a treatment evaluation method, and relates to the technical field of injury condition treatment simulation, and the system comprises a simulation definition module which generates initial vital sign parameters and natural evolution increment under a non-intervention condition according to an injury condition type defined in a treatment scene, the physical injury condition simulation dummy comprises a physical injury condition simulation dummy, a treatment detection module for analyzing and quantifying treatment actions of practicers and generating corresponding intervention signals, a central control module for calculating and outputting vital sign parameters and body surface performance parameters based on pathophysiology laws and an intervention mapping model, and a state feedback module for driving each execution unit of the physical injury condition simulation dummy. The system can analyze and score execution parameters of each treatment action of practicers, generate action quality indexes and intervention signals, provide quantifiable and comparable operation feedback for students, and map treatment action effects to dynamic update of injury states, so that vital signs and body surface manifestation change along with operation.

The invention belongs to the technical field of medical image processing and neural image analysis, and particularly discloses a cerebral apoplexy prognosis prediction method which comprises the following steps: step 1, performing whole cerebral vessel segmentation and morphological feature extraction on a CTA image to obtain 40 blood vessel morphological features; 2, extracting high-throughput omics characteristics from an infarction core and a half-dark band region in the DWI image, and obtaining 1026 image omics characteristics; 3, screening high-resolution features based on minimum absolute contraction and a selection operator, establishing a support vector machine classification model, and predicting a prognosis classification result of a three-month improved Rankin scale of the stroke patient; the deep learning network is used for automatically segmenting the whole brain blood vessel, so that subjective difference of manual recognition is reduced; starting from pathophysiology of occurrence and development of cerebral apoplexy, vascular morphological characteristics and infarction region imageomics characteristics are comprehensively incorporated to carry out prognosis prediction on cerebral apoplexy.

The present invention relates to a method of treating PIK3CA-Related Overgrowth Spectrum (PROS) more particularly, Congenital, Lipomatous, Overgrowth, Vascular Malformations, Epidermal Nevi and Spinal / Skeletal Anomalies and / or Scoliosis (CLOVES) syndrome. To date, there are no specific treatments for patients and no animal models of PROS to better understand the physiopathology of the disorder. Inventors developed a genetic mouse model of PROS that recapitulates the human disease and demonstrated the efficacy of BYL719. Based on these results they treated two patients, one adult and one child, with severe CLOVES syndrome using BYL719. The drug had a robust efficiency on disease in the two patients inducing quick recovery of all affected organs. Thus, the invention relates to a method of treating PROS in a subject in need thereof comprising the step of administrating the subject with a therapeutically effective amount of BYL719.

The present invention relates to a method of treating PIK3CA-Related Overgrowth Spectrum (PROS) more particularly, Congenital, Lipomatous, Overgrowth, Vascular Malformations, Epidermal Nevi and Spinal / Skeletal Anomalies and / or Scoliosis (CLOVES) syndrome. To date, there are no specific treatments for patients and no animal models of PROS to better understand the physiopathology of the disorder. Inventors developed a genetic mouse model of PROS that recapitulates the human disease and demonstrated the efficacy of BYL719. Based on these results they treated two patients, one adult and one child, with severe CLOVES syndrome using BYL719. The drug had a robust efficiency on disease in the two patients inducing quick recovery of all affected organs. Thus, the invention relates to a method of treating PROS in a subject in need thereof comprising the step of administrating the subject with a therapeutically effective amount of BYL719.

Extracellular vesicles and / or exosomes (EVs) remain sparsely studied in hemorrhagic transformations, including stroke and intracranial hemorrhages and could provide key insights into stroke pathophysiology. We assessed plasma levels of neuron-derived EVs (NDEs), astrocyte-derived EVs (ADEs), and oligodendrocyte-derived EVs (ODEs) in 58 patients 5, 15, and 30 days post-ischemic stroke along with 46 matched controls using sandwich immunoassays. Hemorrhagic transformation was a better predictor of ADE levels than lesion volume in linear regression models. These findings suggest that ADE levels are preferentially increased over the first month post-stroke compared to EVs from other neural cell types. ADEs may be of additional interest as biomarkers of blood-brain barrier breakdown to predict hemorrhagic transformation at earlier time points after stroke.

The present invention relates to the field of medical therapy of lesions detrimental to a body. The system is capable of treatment with a non-invasive, ionizing kV energy radiation source. Locally focused energy can be used to definitively treat, or as an adjuvant to enhance immune modulators, to eliminate tumors. Distributed external beam entry points produce a significant advantageous dose profile at depth as intersecting beams accumulate in a narrow focus to treat a selected volume. Targeted disease may have enhanced sensitivity to the radiation by taking up an ionizing-radiation, treatment-localizing agent. This increases the effectiveness of an energy dose in the lesion. The pattern of beam output is effectively directed towards a desired location and kV x-rays traveling towards undesired locations, such as healthy tissue, are quenched. Targeting a lesion within the body with volumetrically discrete energy dose deposition can beneficially impact harmful lesions. Aiming the beam at a pathologic target is done while moving an x-ray source mechanically around a patient to distribute surface dose. The purpose of the focused energy deposition is to destroy and disable pathologic physiology, such as malignant masses. More specifically this invention relates to a system, which optimizes delivery of ionizing kV beams to a lesion alone or one containing treatment-localizing agents in higher concentration than the surrounding normal tissues. Thereby an optimal delivery of ionizing radiation becomes more destructive to a mass of abnormal cells upon interaction with the targeted site.

Compounds and pharmaceutical compositions include inhibitors of apoptosis inducing factor (AIF). Pharmaceutical compositions for the treatment and / or mitigation of diseases in which increased rates of apoptosis are part of the disease pathophysiology, particularly, but not exclusively, when levels or activities of AIF are increased.

The invention relates to the technical field of medical information, and discloses a diabetic neuropathy dynamic early warning method based on deep learning. The method comprises the following steps: acquiring multi-modal physiological data through a sensor array, and converting the multi-modal physiological data into a feature vector sequence through preprocessing and pathophysiology-based mapping; the core of the method is that a dynamic feature selection mechanism is adopted to adaptively screen out a feature subset most related to neuropathy progress to replace a traditional fixed feature set; and constructing a multi-time scale risk prediction model, generating an individualized risk evolution track, and setting a dynamic early warning threshold according to the individualized risk evolution track. And triggering graded early warning by comparing the real-time risk index with a personalized threshold value, and completing adaptive updating of the model. The accuracy of individual risk signal capturing is improved through dynamic feature selection, real prospective early warning is achieved based on a dynamic threshold value of an individual trajectory, and therefore the accuracy and timeliness of early warning are improved.

The present disclosure relates to the use of compound (I) and any of its salts for the treatment of a neoplasm characterized by high expression of toll-like receptor 4 (TLR4) in the tumor or its microenvironment, associated with at least one of the pathophysiological complications including immunosuppression, angiogenesis, fibrosis, or metastasis.

The present disclosure provides methods of training a deep learning (DL)-based classifier to classify a digital histopathology image with respect to a phenotype, methods of classifying a digital histopathology image with respect to a phenotype, and methods of identifying a biological mediator associated with a pathology, pathophysiology, or other clinical characteristic. The disclosure further provides systems for implementation of these methods.

Targeting mitochondrial function is a strategy for preventing metabolic disorders, but restoring mitochondria diurnal regulation remains to be explored. Using targeted metabolomics, we identified 24-hour mitochondrial rhythms promoted by nocturnal time-restricted feeding (TRF) in mice fed a high-fat diet (HFD). Preceding its metabolic benefits, TRF promoted mitochondrial daily rhythms by converging on the enzyme dihydroorotate dehydrogenase (DHODH), which coordinates pyrimidine biosynthesis and mitochondrial oxidative metabolism. The inhibition of DHODH activity by the short half-life inhibitor BAY-2402234 modulated mitochondrial oxidative metabolism, thereby preventing diet-induced obesity, but only when injected at the transition between night and day. This timed inhibition of DHODH promoted oscillations in mitochondrial metabolic pathways and oscillations in the CoQ / CoQH2 ratio, improving metabolic adaptation to the HFD challenge. Our results highlight the role of mitochondrial daily rhythms in the pathophysiology of obesity and open avenues for chronopharmacological treatments targeting these rhythms. Thus, the present invention pertains to a method for treating or preventing obesity in a subject in need thereof. This method includes administering to the subject, at a specific time of the circadian rhythm, a therapeutically effective amount of a dihydroorotate dehydrogenase inhibitor that exhibits an inhibitory duration of less than 24 hours, and more specifically, a short half-life of less than 24 hours.

TRPV1 is an integral cation channel widely expressed in various tissues and involved in critical biological functions, such as thermosensation. It is polymodally activated by distinct stimuli, including chemical ligands, heat, and protons (pH). However, dozens of clinical trials targeting various types of TRPV1 -mediated pain have generally failed, primarily due to hyperthermia (increased body temperature). Meta-analysis of clinical data suggests that mode-selectivity is essential to realizing the therapeutic potential of TRPV1. TRPV1 is regulated allosterically, with vanilloids and other chemical ligands binding to the voltage-sensing-like domain (VSLD), resulting in the gating of the pore domain. Therefore, compositions and methods for modulating TRPV1 to treat human pathophysiologies, such as pain, are described herein.

This invention relates to the field of medical image processing technology, specifically to an automatic detection and classification method and system for intracranial hemorrhage based on three-window CT fusion and label-dependent graph neural network, including the following steps: S100, acquiring the original CT slice image of the head to be detected, performing grayscale mapping on the original slice image based on preset brain window, subdural window and bone window respectively, and stacking the three mapped images along the channel dimension to generate a three-channel fused image; This invention greatly enriches the model's global perception ability of multi-level physiological structures such as brain parenchyma, microhematomas and skull lesions through innovative three-window physical mapping and channel fusion; it introduces a hybrid adjacency matrix graph neural network that combines prior knowledge of neuroradiology with data-driven approach, explicitly establishing pathophysiological causal relationships between various hemorrhage subtypes at the model architecture level, effectively eliminating logical contradictions in predictions that violate clinical common sense.

This application relates to the field of biomedical signal processing and discloses a method for identifying postoperative intestinal dysfunction based on intestinal stimulation feedback, comprising the following steps: S1. A linear frequency modulated (LFM) scanning signal is emitted to the abdomen of the subject, and the mechanical vibration response signal of the abdominal medium to the LFM scanning signal is acquired. The dominant mechanical response frequency characterizing the abdominal medium in the current state is calculated and determined based on the LFM scanning signal and the mechanical vibration response signal. The dominant mechanical response frequency of the intestinal tissue is locked by baseline scanning, and resonant micro-perturbation is implemented at this frequency. The stress response of the intestine is captured synchronously using a dual-modal sensor of mechanical and electrophysiological sensors. By calculating the two-dimensional feature vector composed of the phase-locked value and the dynamic mechanical input impedance, the system can accurately distinguish between a simple decrease in electrical activity and a high-tension state caused by obstruction, thereby providing clinicians with a deeper pathophysiological diagnostic basis.

A method may include identifying a simulated three-dimensional representation corresponding to an internal anatomy of a subject based on a match between a computed two-dimensional image corresponding to the simulated three-dimensional representation and a two-dimensional image depicting the internal anatomy of the subject. Simulations of the electrical activities measured by a recording device with standard lead placement and nonstandard lead placement may be computed based on the simulated three-dimensional representation. A clinical electrogram and / or a clinical vectorgram for the subject may be corrected based on a difference between the simulations of electrical activities to account for deviations arising from patient-specific lead placement as well as variations in subject anatomy and pathophysiology.

Provided herein include compounds, compositions, kits and methods for preventing and treating psychiatric disorders. The composition and methods described herein can prophylactically treat a subject prior to and / or after a stressor and / or prior to the recurrence of a stressor, thereby preventing or delaying a relapse of depression or depression-like and / or stress-induced behaviors and disorders. The composition can comprise a serotonin 4 receptor (S-HUR) agonist and an N- methyl-D-aspartate (NMDAR) antagonist and a pharmaceutically acceptable salt, analog, derivative or metabolite thereof.

The invention relates to the technical field of medical image analysis, and particularly discloses a three-dimensional reconstruction and risk prediction system and method based on preoperative image features. The method comprises the following steps: acquiring an MRI / CT image and segmenting a focus area; constructing a pathophysiology knowledge graph; and fusing the space and the pathological rule to construct a dynamic graph structure. The method is characterized in that a graph convolutional neural network is adopted to aggregate and update graph node features, and multi-focus joint three-dimensional reconstruction is realized; and a graph attention mechanism is used to calculate a risk conduction weight conforming to a pathological law between focuses, and finally a joint risk thermodynamic diagram fusing prior knowledge is generated. According to the method, data driving and knowledge driving are deeply fused through the neural network model, the defect that relevance between lesions is neglected in a traditional method is overcome, high-precision three-dimensional reconstruction and accurate risk prediction are achieved, and intelligent decision support is provided for preoperative planning.

The present disclosure provides for imaging agents and methods of making and using the same. The imaging agent comprises a luminol component comprising a luminol moiety or functional analogue thereof; a chelator; a linker group bonding or complexing the luminol component to the chelator; and a radiolabel component bound to the chelator. The imaging agent described herein is capable of monitoring, targeting, or imaging oxidative stress, reactive oxygen species (ROS), superoxide generation, or hydrogen peroxide generation, mediating pathophysiology of different disease states.

The present invention relates to a method of treating PIK3CA-Related Overgrowth Spectrum (PROS) more particularly, Congenital, Lipomatous, Overgrowth, Vascular Malformations, Epidermal Nevi and Spinal / Skeletal Anomalies and / or Scoliosis (CLOVES) syndrome. To date, there are no specific treatments for patients and no animal models of PROS to better understand the physiopathology of the disorder. Inventors developed a genetic mouse model of PROS that recapitulates the human disease and demonstrated the efficacy of BYL719. Based on these results they treated two patients, one adult and one child, with severe CLOVES syndrome using BYL719. The drug had a robust efficiency on disease in the two patients inducing quick recovery of all affected organs. Thus, the invention relates to a method of treating PROS in a subject in need thereof comprising the step of administrating the subject with a therapeutically effective amount of BYL719.

AMD is a complex, multifactorial disease lacking curative therapy. Understanding of AMD pathophysiology highlights mechanisms such as mitochondrial dysfunction, visual cycle defects, autophagy impairment, and unresolved inflammation and oxidative stress. However, current therapies only target select aspects of AMD pathology. As described herein, variants in the ELOVL2 gene are utilized to predict the progression of age-related central nervous system conditions, including AMD, and to assess susceptibility to treatment. This approach enables more effective early intervention and personalized therapeutic strategies.

The present invention relates to a composition containing gintonin as an active ingredient for the prevention and treatment of ischemic cerebrovascular disorders, including cerebral infarction. The gintonin of the present invention can reduce the volume of cerebral infarction and increase survival rates after cerebral infarction, making it useful for the prevention and treatment of cerebral infarction. Furthermore, pretreatment of human brain microvascular endothelial cells (HBMECs) with gintonin has been shown to have neuroprotective and injury-preventing effects, while posttreatment with gintonin has been shown to have neuroprotective and therapeutic effects. Mechanism verification revealed that gintonin is effective in restoring reduced nitric oxide (NO) levels, which are known to be involved in the onset and pathophysiology of cerebral infarction. Therefore, the use of the present invention may improve the prevention and treatment of ischemic cerebrovascular disorders, including cerebral infarction, and reduce medical costs.

The present invention discloses systems and methods for mapping gastric activity with an electrode array patch disposed over an abdomen skin surface of a patient. A method may include measuring electrical signals associated with gastric activity of the patient with the electrode array patch over a predetermined time period and concurrently receiving patient symptom information, determining one or more normalized biometrics from the measured electrical signals, correlating the one or more normalized biometrics and the patient symptom information, determining a measure of correlation, determining a measure of temporal association, and determining a gastrointestinal phenotype of the patient based at least in part on the measure of correlation and the measure of temporal association. The present invention advantageously enables mapping of gut motility patterns at high spatial resolution for the identification of gastric disorders and provides biomarkers of pathophysiology which include correlations with symptom severity profiles.

Marfan syndrome is caused by mutations in the FBN1 gene (15q21) that codes for Fibrillin-1, an essential connective tissue protein and is a pathology responsible for a high morbidity and mortality. Apart from surgery, treatment options are limited. It is therefore essential to develop new pharmacological approaches to limit aortic dilatation and / or rupture. The inventors have demonstrated a critical role for TREM-2 in the pathophysiology of ascending aortopathy related to Marfan disease. Deletion of TREM-2 indeed aggravates ascending aorta dilation and rupture. Stimulating TREM-2 receptor with peptide or agonistic monoclonal antibody represent a new therapeutic approach for Marfan syndrome.

Described herein are detecting methods for conformational disease, aging and proteinopathies, by measuring the presence of b-isox-precipitates and the levels of b-isox-captured proteins in biofluids of healthy individuals and patients. Research identified additional biomarkers, which made it possible to detect, diagnose or treat, a human disease in a human subject by, with or without adding an isoxazole to an obtained biofluid sample, detecting the biomarker. Use of b-iso and / or biomarkers for diagnosing the disease are made possible.

Provided herein are irradiated mouse models which recapitulate the effects of ionizing radiation-induced microglia activation, eye injury and retinal degeneration, as well as methods for producing such mouse models. These mouse models are useful, for example, for the study of genes involved in the pathophysiology of retinal degeneration and for the development of methods for treating retinal degeneration in humans.

The present invention discloses a rabbit hybridoma monoclonal antibody against mouse BP180NC14A, a preparation method, an application, and a hybridoma cell line. The monoclonal antibody is specific for the polypeptide encoded by nucleotides 499-573 in Q07563-1 (i.e., the amino acid sequence shown in SEQ ID No. 1). The beneficial effects of the present invention are embodied in providing a monoclonal antibody against mouse BP180NC14A, its preparation and application, and a rabbit hybridoma cell line producing the monoclonal antibody. These antibodies provide a basis for further clarifying the pathophysiological research of BP180 in skin tissue, and can be used to induce a mouse bullous pemphigoid (BP) model or detect anti-BP180 IgG titers in mice, thus having important application prospects.

The invention relates to the technical field of experimental animal model construction in biomedical research, and discloses a common bile duct flow limiting tube for constructing a chronic cholestasis rat model and a construction method, the flow limiting tube comprises a hard tubular body and a soft protective fixing wing wrapping the tubular body, the inner diameter of the tubular body is 0.12-0.15 mm, and the outer diameter of the tubular body is 0.12-0.15 mm. The length of the tubular body is 0.5 to 0.8 cm; protruding fixing rings are arranged at the two ends of the protection fixing wing, and the total outer diameter of the flow limiting pipe is smaller than or equal to 0.7 mm. The common bile duct flow limiting tube is implanted into the specified position of the common bile duct of an experimental animal through a precise operation, precise control over bile flow is achieved, and therefore a standardized animal model capable of highly simulating the human chronic cholestatic liver disease in the aspects of the pathological process, physiological compensation and systematic expression is established. The model and the construction method thereof can be directly applied to multiple directions of liver pathophysiology mechanism research, drug target verification, new drug curative effect and safety evaluation and the like.

The invention discloses a blood vessel-cell microenvironment visualization model multi-parameter fusion analysis method based on the combination of DCE-MRI and DWI. The blood vessel-cell microenvironment visualization model multi-parameter fusion analysis method based on the combination of DCE-MRI and DWI comprises the following steps: constructing an LCBM blood vessel-cell microenvironment visualization model by quantifying parameters such as Ktrans, Vp and ADC; specifically, the research aims to clarify DCE-MRI / DWI characteristic spectrums of different tissue pathology subtypes of LCBM and reveal blood vessel-cell microenvironment characteristics of the LCBM, and the innovation of the research lies in that DCE-MRI blood vessel function parameters and DWI structure parameters are integrated for the first time, a blood vessel-cell microenvironment visualization model of the LCBM is constructed, and the blood vessel-cell microenvironment visualization model of the LCBM is established. An iconography basis is provided for precise typing of the LCBM and selection of an anti-vascular treatment target region, a new tool is provided for pathophysiology evaluation of the LCBM, and an iconography foundation is laid for an individualized treatment strategy targeting the pathophysiology of the LCBM.